Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069192 | 0.82 | HPGD (0.41) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2069190 | 0.82 | SMN1; SMN2 (0.37) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2068081 | 0.79 | TLR8 (0.36) | — | |
| SCHEMBL2068079 | 0.79 | TUBB4A (0.35) | — | |
| SCHEMBL1674701 | 0.77 | — | — | |
| SCHEMBL2066425 | 0.76 | — | — | |
| SCHEMBL2066424 | 0.76 | — | — | |
| SCHEMBL1965518 | 0.76 | — | — | |
| SCHEMBL3431780 | 0.76 | — | — | |
| SCHEMBL3431812 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 786 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | claimed |
| CN-114206886-A | Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same | 广东聚华印刷显示技术有限公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2022015977-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | claimed |
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | claimed |
| WO-2021016814-A1 | LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2021-02-04 | — | — | WO | claimed |
| EP-3157922-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2018-11-28 | — | — | EP | claimed |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | claimed |
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-07-19 | — | — | US | claimed |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BY) | 2018-06-19 | — | — | US | claimed |
| US-9969748-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | claimed |
| US-5792776-A | HYDROXAMIC SUBSTITUTED TETRAHYDROTHIPOHENES, TETRAHYDROFURANS, PYRROLIDINES AND CYCLOPENTANES | CYTOMED, INC., (US) | 1998-08-11 | — | — | US | claimed |
| US-5780503-A | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders | CYTOMED, INC. (US) | 1998-07-14 | — | — | US | claimed |
| US-5750565-A | TETRAHYDROFURANS, TETRAHYDROTHIOPHENES, PYRROLIDINES AND CYCLOPENTANES | CYTOMED, INC. (US) | 1998-05-12 | — | — | US | claimed |
| EP-0770064-A4 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 1998-01-14 | — | — | EP | claimed |
| US-5703093-A | INHIBITORS OF 5-LIPOXYGENASE | CYTOMED, INC. (US) | 1997-12-30 | — | — | US | claimed |
| EP-0770064-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1997-05-02 | — | — | EP | claimed |
| WO-1996000212-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1996-01-04 | — | — | WO | claimed |
| EP-0017680-B1 | PYRIMIDONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-04-21 | — | — | EP | claimed |
| US-4255428-A | ANTIINFLAMMATORY AGENTS, HISTAMINE BLOCKING AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-03-10 | — | — | US | claimed |
| EP-0017680-A1 | Pyrimidone derivatives, process for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | CA12 4584/4885CA1 3360/4885CA2 3005/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CA12 4119/4885CA1 4409/4885CA2 1475/4885 |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2A | CA12 4835/4885CA1 4223/4885CA2 3632/4885 |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | PI4KB, PI4KA, PI4K2B | CA12 4659/4885CA1 3603/4885CA2 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.